Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging
Clinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profiles alongside histopathology and imaging findings. While the World Health Organization (WHO) guideline recommends the genotyping of informative alterations as a routine clinical practice for...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/21/5198 |
| _version_ | 1797632095964626944 |
|---|---|
| author | Nastaran Khalili Hossein Shooli Nastaran Hosseini Anahita Fathi Kazerooni Ariana Familiar Sina Bagheri Hannah Anderson Stephen J. Bagley Ali Nabavizadeh |
| author_facet | Nastaran Khalili Hossein Shooli Nastaran Hosseini Anahita Fathi Kazerooni Ariana Familiar Sina Bagheri Hannah Anderson Stephen J. Bagley Ali Nabavizadeh |
| author_sort | Nastaran Khalili |
| collection | DOAJ |
| description | Clinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profiles alongside histopathology and imaging findings. While the World Health Organization (WHO) guideline recommends the genotyping of informative alterations as a routine clinical practice for central nervous system (CNS) tumors, the acquisition of tumor tissue in the CNS is invasive and not always possible. Liquid biopsy is a non-invasive approach that provides the opportunity to capture the complex molecular heterogeneity of the whole tumor through the detection of circulating tumor biomarkers in body fluids, such as blood or cerebrospinal fluid (CSF). Despite all of the advantages, the low abundance of tumor-derived biomarkers, particularly in CNS tumors, as well as their short half-life has limited the application of liquid biopsy in clinical practice. Thus, it is crucial to identify the factors associated with the presence of these biomarkers and explore possible strategies that can increase the shedding of these tumoral components into biological fluids. In this review, we first describe the clinical applications of liquid biopsy in CNS tumors, including its roles in the early detection of recurrence and monitoring of treatment response. We then discuss the utilization of imaging in identifying the factors that affect the detection of circulating biomarkers as well as how image-guided interventions such as focused ultrasound can help enhance the presence of tumor biomarkers through blood–brain barrier (BBB) disruption. |
| first_indexed | 2024-03-11T11:33:00Z |
| format | Article |
| id | doaj.art-c67f5008f9984601835fe82e034affe5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T11:33:00Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c67f5008f9984601835fe82e034affe52023-11-10T15:00:12ZengMDPI AGCancers2072-66942023-10-011521519810.3390/cancers15215198Adding Value to Liquid Biopsy for Brain Tumors: The Role of ImagingNastaran Khalili0Hossein Shooli1Nastaran Hosseini2Anahita Fathi Kazerooni3Ariana Familiar4Sina Bagheri5Hannah Anderson6Stephen J. Bagley7Ali Nabavizadeh8Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USADepartment of Radiology, Bushehr University of Medical Sciences, Bushehr 75146-33196, IranSchool of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, IranCenter for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USACenter for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USADepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USACenter for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USAClinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profiles alongside histopathology and imaging findings. While the World Health Organization (WHO) guideline recommends the genotyping of informative alterations as a routine clinical practice for central nervous system (CNS) tumors, the acquisition of tumor tissue in the CNS is invasive and not always possible. Liquid biopsy is a non-invasive approach that provides the opportunity to capture the complex molecular heterogeneity of the whole tumor through the detection of circulating tumor biomarkers in body fluids, such as blood or cerebrospinal fluid (CSF). Despite all of the advantages, the low abundance of tumor-derived biomarkers, particularly in CNS tumors, as well as their short half-life has limited the application of liquid biopsy in clinical practice. Thus, it is crucial to identify the factors associated with the presence of these biomarkers and explore possible strategies that can increase the shedding of these tumoral components into biological fluids. In this review, we first describe the clinical applications of liquid biopsy in CNS tumors, including its roles in the early detection of recurrence and monitoring of treatment response. We then discuss the utilization of imaging in identifying the factors that affect the detection of circulating biomarkers as well as how image-guided interventions such as focused ultrasound can help enhance the presence of tumor biomarkers through blood–brain barrier (BBB) disruption.https://www.mdpi.com/2072-6694/15/21/5198liquid biopsybrain tumorimagingMRIPET/MRIcell-free DNA |
| spellingShingle | Nastaran Khalili Hossein Shooli Nastaran Hosseini Anahita Fathi Kazerooni Ariana Familiar Sina Bagheri Hannah Anderson Stephen J. Bagley Ali Nabavizadeh Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging Cancers liquid biopsy brain tumor imaging MRI PET/MRI cell-free DNA |
| title | Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging |
| title_full | Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging |
| title_fullStr | Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging |
| title_full_unstemmed | Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging |
| title_short | Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging |
| title_sort | adding value to liquid biopsy for brain tumors the role of imaging |
| topic | liquid biopsy brain tumor imaging MRI PET/MRI cell-free DNA |
| url | https://www.mdpi.com/2072-6694/15/21/5198 |
| work_keys_str_mv | AT nastarankhalili addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT hosseinshooli addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT nastaranhosseini addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT anahitafathikazerooni addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT arianafamiliar addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT sinabagheri addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT hannahanderson addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT stephenjbagley addingvaluetoliquidbiopsyforbraintumorstheroleofimaging AT alinabavizadeh addingvaluetoliquidbiopsyforbraintumorstheroleofimaging |